This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Congress must pass legislation to increase pharmaceutical pricing transparency and rein-in pharmacy benefit managers.
U.S. and global drug companies say they will continue manufacturing and selling their products in Russia.
PhRMA regards drug price negotiation for Medicare as an existential threat to its business — potentially costing billions.
Congress created the 340B program to provide extra funding for hospitals and clinics, but some pharmaceutical manufacturers are refusing to honor the federal drug discount program.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
A look at the policies on the table and what they will and won’t do to rein-in the cost of pharmaceuticals.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Activists demonstrated outside the U.S. Congressman's Oregon City district office in protest of his vote opposing a proposal to lower prescription drug prices.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.
The report, which failed to disclose conflicts of interest, advised against an effort by Medicare to recoup millions for discarded drugs.
Pharmacy benefit managers switched to virtual audits during the pandemic, which increased reviews, payment denials and their profits.
Ozempic’s peppy ads suggest that people who use it might lose weight, but also include a disclaimer: that it “is not a weight loss drug.” Now — as Wegovy — it is.
